{"groups":[{"description":"Patients with a deleterious BRCA (breast cancer susceptibility gene) mutation detected in their tumor. Part 1 enrolled patients who received ≥ 1 prior platinum-based regimen and had platinum-sensitive disease.","id":"FG000","title":"Part 1: tBRCA"},{"description":"Patients without a BRCA mutation in their tumor, but have high LOH (loss of heterozygosity). Part 1 enrolled patients received ≥ 1 prior platinum-based regimen and had platinum-sensitive disease.","id":"FG001","title":"Part 1: Non-tBRCA LOH+"},{"description":"Patients without a BRCA mutation in their tumor, but have low LOH. Part 1 enrolled patients received ≥ 1 prior platinum-based regimen and had platinum-sensitive disease.","id":"FG002","title":"Part 1: Non-tBRCA LOH-"},{"description":"Patients without a BRCA mutation in their tumor, and have unknown LOH due to missing results and/or failed test result(s). Part 1 enrolled patients received ≥ 1 prior platinum-based regimen and had platinum-sensitive disease.","id":"FG003","title":"Part 1: Non-tBRCA LOH Unknown"},{"description":"Patients with a deleterious BRCA mutation detected in their tumor. Part 2 enrolled patients who received at least 3, but no more than 4, prior chemotherapy regimens.","id":"FG004","title":"Part 2: tBRCA"},{"description":"Patients without a BRCA mutation in their tumor, but have high LOH. Part 2 enrolled patients who received at least 3, but no more than 4, prior chemotherapy regimens.","id":"FG005","title":"Part 2: Non-tBRCA LOH+"},{"description":"Patients without a BRCA mutation in their tumor, but have low LOH. Part 2 enrolled patients who received at least 3, but no more than 4, prior chemotherapy regimens.","id":"FG006","title":"Part 2: Non-tBRCA LOH-"},{"description":"Patients without a BRCA mutation in their tumor, and have unknown LOH due to missing results and/or failed test result(s). Part 2 enrolled patients who received at least 3, but no more than 4, prior chemotherapy regimens.","id":"FG007","title":"Part 2: Non-tBRCA LOH Unknown"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}],"type":"Ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"82"},{"groupId":"FG002","numSubjects":"70"},{"groupId":"FG003","numSubjects":"12"},{"groupId":"FG004","numSubjects":"84"},{"groupId":"FG005","numSubjects":"73"},{"groupId":"FG006","numSubjects":"107"},{"groupId":"FG007","numSubjects":"23"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"80"},{"groupId":"FG002","numSubjects":"70"},{"groupId":"FG003","numSubjects":"11"},{"groupId":"FG004","numSubjects":"80"},{"groupId":"FG005","numSubjects":"72"},{"groupId":"FG006","numSubjects":"107"},{"groupId":"FG007","numSubjects":"23"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"491 subjects were recruited from 64 sites across 6 countries."}